Feasibility of Ambulatory Talc. Pleurodesis

Recruiting now · Not applicable

Conditions studied: Malignant Pleural Effusion, Malignancy, Palliative Care

In brief

Patients with malignant pleural disease often experience a significant symptom burden and a short life expectancy. The cornerstone of their treatment is relieving breathlessness by draining fluid from around the lungs and attempting to prevent further fluid build up. Inpatient chest drainage and talc pleurodesis remains the most successful method of stopping the fluid build up but this often requires an average hospital stay of four days. This can be an inappropriate length of time for this patient group. Our study would investigate whether this treatment could be provided on an outpatient, ambulatory basis and facilitate a greater quality of life. The investigators would assess deliverability of the trial protocol and collect patient feedback to see if our patients consider it an acceptable and worthwhile intervention.

Key facts

Study ID

NCT06682936

Run by

David Rollins

People needed

15

Starts

2024-01-10

Expected to finish

2025-02-01

Last updated by the study team

2024-11-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Malignant pleural effusion
• Life expectancy >30 days
• WHO PS 1-2 (3 if due to dyspnoea)

You may not qualify if…

• Previous failed pleurodesis (on affected side)
• Known non-expansile lung

Where it is running

• North Tees and Hartlepool NHS foundation trust — Stockton-on-Tees, County Durham, United Kingdom (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.